3 recherche sur le mot-clé 'Insulin-like growth factor-1'

Association of Thyroid Hormone and Insulin-Like Growth Factor-1 Levels With Autism Spectrum Disorders: A Systematic Review and Meta-Analysis / Xingxing LIAO ; Kaiyue HAN ; Maoyuan NIU ; Jiarou CHEN ; Xianna WANG ; Jianjun LIU ; Yan ZHANG ; Hao ZHANG in Autism Research, 18-7 (July 2025)  

Public ISBD [article]  inAutism Research > 18-7 (July 2025) . - p.1497-1512 Titre : Association of Thyroid Hormone and Insulin-Like Growth Factor-1 Levels With Autism Spectrum Disorders: A Systematic Review and Meta-Analysis Type de document : texte imprimé Auteurs : Xingxing LIAO, Auteur ; Kaiyue HAN, Auteur ; Maoyuan NIU, Auteur ; Jiarou CHEN, Auteur ; Xianna WANG, Auteur ; Jianjun LIU, Auteur ; Yan ZHANG, Auteur ; Hao ZHANG, Auteur Article en page(s) : p.1497-1512 Langues : Anglais (eng) Mots-clés : autism spectrum disorder  insulin-like growth factor-1  meta-analysis  systematic review  thyroid hormone Index. décimale : PER Périodiques Résumé : ABSTRACT The action of the thyroid hormones and insulin-like growth factor 1 (IGF-1) is interdependent. The levels of thyroid hormone and IGF-1 were reported to be altered in individuals with autism spectrum disorder (ASD), but the results were controversial. This study aims to compare levels of thyroxine, triiodothyronine, thyroid stimulating hormone, and IGF-1 between the ASD group and neurotypical controls. PubMed, Web of Science, Cochrane, and Embase databases were searched for eligible observational studies. We calculated pooled standardized mean difference (SMD) with 95% confidence intervals (CIs) of our data using a random or fixed effect model. The search strategy provided a total of 1710 articles, of which 16 articles were quantitatively analyzed. The total number of included participants was 2399 (1285 cases and 1114 controls). The meta-analysis revealed no significantly changed blood levels of thyroxine, free triiodothyronine, free thyroxine, and IGF-1 of subjects with ASD compared to non-autistic controls. The blood TSH levels were significantly lower in ASD subjects than in controls (n 859, Hedges' g 1.18, 95% CI: 2.17 to 0.20, p 0.02). Subgroup-analysis results showed that blood free triiodothyronine (n 153, Hedges' g 0.74, 95% CI: 1.08 to 0.40, p?< 0.0001, I2 2%), free thyroxine (n 153, Hedges' g 0.72, 95% CI: 1.31 to 0.14, p 0.02, I2 66%), and IGF-1 (n 397; Hedges' g 0.92; 95% CI: 1.30 to 0.55, p?< 0.00001, I2 63%) levels were significantly reduced in subjects with severe ASD symptoms. Individuals with severe ASD may experience a dysfunction of the hypothalamic?pituitary?thyroid axis, and further studies are warranted to determine the correlation between thyroid hormone and IGF-1 levels and disease severity. Trial Registration: ClinicalTrials.gov identifiers: NCT01970345 En ligne : https://doi.org/10.1002/aur.70052 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=565 [article] Association of Thyroid Hormone and Insulin-Like Growth Factor-1 Levels With Autism Spectrum Disorders: A Systematic Review and Meta-Analysis [texte imprimé] / Xingxing LIAO, Auteur ; Kaiyue HAN, Auteur ; Maoyuan NIU, Auteur ; Jiarou CHEN, Auteur ; Xianna WANG, Auteur ; Jianjun LIU, Auteur ; Yan ZHANG, Auteur ; Hao ZHANG, Auteur . - p.1497-1512. Langues : Anglais (eng) in Autism Research > 18-7 (July 2025) . - p.1497-1512 Mots-clés : autism spectrum disorder  insulin-like growth factor-1  meta-analysis  systematic review  thyroid hormone Index. décimale : PER Périodiques Résumé : ABSTRACT The action of the thyroid hormones and insulin-like growth factor 1 (IGF-1) is interdependent. The levels of thyroid hormone and IGF-1 were reported to be altered in individuals with autism spectrum disorder (ASD), but the results were controversial. This study aims to compare levels of thyroxine, triiodothyronine, thyroid stimulating hormone, and IGF-1 between the ASD group and neurotypical controls. PubMed, Web of Science, Cochrane, and Embase databases were searched for eligible observational studies. We calculated pooled standardized mean difference (SMD) with 95% confidence intervals (CIs) of our data using a random or fixed effect model. The search strategy provided a total of 1710 articles, of which 16 articles were quantitatively analyzed. The total number of included participants was 2399 (1285 cases and 1114 controls). The meta-analysis revealed no significantly changed blood levels of thyroxine, free triiodothyronine, free thyroxine, and IGF-1 of subjects with ASD compared to non-autistic controls. The blood TSH levels were significantly lower in ASD subjects than in controls (n 859, Hedges' g 1.18, 95% CI: 2.17 to 0.20, p 0.02). Subgroup-analysis results showed that blood free triiodothyronine (n 153, Hedges' g 0.74, 95% CI: 1.08 to 0.40, p?< 0.0001, I2 2%), free thyroxine (n 153, Hedges' g 0.72, 95% CI: 1.31 to 0.14, p 0.02, I2 66%), and IGF-1 (n 397; Hedges' g 0.92; 95% CI: 1.30 to 0.55, p?< 0.00001, I2 63%) levels were significantly reduced in subjects with severe ASD symptoms. Individuals with severe ASD may experience a dysfunction of the hypothalamic?pituitary?thyroid axis, and further studies are warranted to determine the correlation between thyroid hormone and IGF-1 levels and disease severity. Trial Registration: ClinicalTrials.gov identifiers: NCT01970345 En ligne : https://doi.org/10.1002/aur.70052 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=565

Clinical trial of insulin-like growth factor-1 in Phelan-McDermid syndrome / Alexander KOLEVZON in Molecular Autism, 13 (2022)  

Public ISBD [article]  inMolecular Autism > 13 (2022) . - 17 p. Titre : Clinical trial of insulin-like growth factor-1 in Phelan-McDermid syndrome Type de document : texte imprimé Auteurs : Alexander KOLEVZON, Auteur ; Michael S. BREEN, Auteur ; Paige M. SIPER, Auteur ; Danielle B. HALPERN, Auteur ; Yitzchak FRANK, Auteur ; H. RIEGER, Auteur ; J. WEISMANN, Auteur ; Maria Del Pilar TRELLES, Auteur ; Bonnie LERMAN, Auteur ; Robert RAPAPORT, Auteur ; Joseph D. BUXBAUM, Auteur Article en page(s) : 17 p. Langues : Anglais (eng) Mots-clés : Child  Chromosome Deletion  Chromosome Disorders/drug therapy/genetics  Chromosomes, Human, Pair 22  Humans  Insulin-Like Growth Factor I/therapeutic use  Pilot Projects  Asd  Autism spectrum disorder  Igf-1  Insulin-like growth factor-1  Pms  Phelan-McDermid syndrome  shank3 Index. décimale : PER Périodiques Résumé : BACKGROUND: Phelan-McDermid syndrome (PMS) is caused by haploinsufficiency of the SHANK3 gene and is characterized by global developmental delays and autism spectrum disorder (ASD). Based on several converging lines of preclinical and clinical evidence supporting the use of insulin-like growth factor-1 (IGF-1) in PMS, this study aims to follow-up a previous pilot study with IGF-1 to further evaluate this novel therapeutic for core symptoms of ASD in children with PMS. METHODS: Ten children aged 5-9 with PMS were enrolled. Participants were randomized to receive IGF-1 or placebo (saline) using a 12-week, double-blind, crossover design. Efficacy was assessed using the primary outcome of the Aberrant Behavior Checklist-Social Withdrawal (ABC-SW) subscale as well as secondary outcome measures reflecting core symptoms of ASD. To increase power and sample size, we jointly analyzed the effect of IGF-1 reported here together with results from our previous controlled trail of IGF-1 in children with PMS (combined N=19). RESULTS: Results on the ABC-SW did not reach statistical significance, however significant improvements in sensory reactivity symptoms were observed. In our pooled analyses, IGF-1 treatment also led to significant improvements in repetitive behaviors and hyperactivity. There were no other statistically significant effects seen across other clinical outcome measures. IGF-1 was well tolerated and there were no serious adverse events. LIMITATIONS: The small sample size and expectancy bias due to relying on parent reported outcome measures may contribute to limitations in interpreting results. CONCLUSION: IGF-1 is efficacious in improving sensory reactivity symptoms, repetitive behaviors, and hyperactivity in children with PMS. Trial registration NCT01525901. En ligne : http://dx.doi.org/10.1186/s13229-022-00493-7 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=477 [article] Clinical trial of insulin-like growth factor-1 in Phelan-McDermid syndrome [texte imprimé] / Alexander KOLEVZON, Auteur ; Michael S. BREEN, Auteur ; Paige M. SIPER, Auteur ; Danielle B. HALPERN, Auteur ; Yitzchak FRANK, Auteur ; H. RIEGER, Auteur ; J. WEISMANN, Auteur ; Maria Del Pilar TRELLES, Auteur ; Bonnie LERMAN, Auteur ; Robert RAPAPORT, Auteur ; Joseph D. BUXBAUM, Auteur . - 17 p. Langues : Anglais (eng) in Molecular Autism > 13 (2022) . - 17 p. Mots-clés : Child  Chromosome Deletion  Chromosome Disorders/drug therapy/genetics  Chromosomes, Human, Pair 22  Humans  Insulin-Like Growth Factor I/therapeutic use  Pilot Projects  Asd  Autism spectrum disorder  Igf-1  Insulin-like growth factor-1  Pms  Phelan-McDermid syndrome  shank3 Index. décimale : PER Périodiques Résumé : BACKGROUND: Phelan-McDermid syndrome (PMS) is caused by haploinsufficiency of the SHANK3 gene and is characterized by global developmental delays and autism spectrum disorder (ASD). Based on several converging lines of preclinical and clinical evidence supporting the use of insulin-like growth factor-1 (IGF-1) in PMS, this study aims to follow-up a previous pilot study with IGF-1 to further evaluate this novel therapeutic for core symptoms of ASD in children with PMS. METHODS: Ten children aged 5-9 with PMS were enrolled. Participants were randomized to receive IGF-1 or placebo (saline) using a 12-week, double-blind, crossover design. Efficacy was assessed using the primary outcome of the Aberrant Behavior Checklist-Social Withdrawal (ABC-SW) subscale as well as secondary outcome measures reflecting core symptoms of ASD. To increase power and sample size, we jointly analyzed the effect of IGF-1 reported here together with results from our previous controlled trail of IGF-1 in children with PMS (combined N=19). RESULTS: Results on the ABC-SW did not reach statistical significance, however significant improvements in sensory reactivity symptoms were observed. In our pooled analyses, IGF-1 treatment also led to significant improvements in repetitive behaviors and hyperactivity. There were no other statistically significant effects seen across other clinical outcome measures. IGF-1 was well tolerated and there were no serious adverse events. LIMITATIONS: The small sample size and expectancy bias due to relying on parent reported outcome measures may contribute to limitations in interpreting results. CONCLUSION: IGF-1 is efficacious in improving sensory reactivity symptoms, repetitive behaviors, and hyperactivity in children with PMS. Trial registration NCT01525901. En ligne : http://dx.doi.org/10.1186/s13229-022-00493-7 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=477

A proof-of-concept study of growth hormone in children with Phelan-McDermid syndrome / S. SETHURAM in Molecular Autism, 13 (2022)  

Public ISBD [article]  inMolecular Autism > 13 (2022) . - 6p. Titre : A proof-of-concept study of growth hormone in children with Phelan-McDermid syndrome Type de document : texte imprimé Auteurs : S. SETHURAM, Auteur ; Tess LEVY, Auteur ; Jennifer H. FOSS-FEIG, Auteur ; Danielle B. HALPERN, Auteur ; Sven SANDIN, Auteur ; Paige M. SIPER, Auteur ; Hugh WALKER, Auteur ; Joseph D. BUXBAUM, Auteur ; Robert RAPAPORT, Auteur ; Alexander KOLEVZON, Auteur Article en page(s) : 6p. Langues : Anglais (eng) Mots-clés : Asd  Autism spectrum disorder  Growth hormone  Igf-1  Insulin-like growth factor-1  Pms  Phelan–McDermid syndrome  Shank3  Jaguar, Neuren, GW Pharma, and Ovid Therapeutics. JDB has a shared patent with Mount  Sinai for IGF-1 in Phelan–McDermid syndrome. No other authors have competing  interests to disclose. Index. décimale : PER Périodiques Résumé : BACKGROUND: Phelan-McDermid syndrome (PMS) is caused by 22q13 deletions including SHANK3 or pathogenic sequence variants in SHANK3 and is among the more common rare genetic findings in autism spectrum disorder (ASD). SHANK3 is critical for synaptic function, and preclinical and clinical studies suggest that insulin-like growth factor-1 (IGF-1) can reverse a range of deficits in PMS. IGF-1 release is stimulated by growth hormone secretion from the anterior pituitary gland, and this study sought to assess the feasibility of increasing IGF-1 levels through recombinant human growth hormone (rhGH) treatment, in addition to establishing safety and exploring efficacy of rhGH in children with PMS. METHODS: rhGH was administered once daily for 12 weeks to six children with PMS using an open-label design. IGF-1 levels, safety, and efficacy assessments were measured every 4 weeks throughout the study. RESULTS: rhGH administration increased levels of IGF-1 by at least 2 standard deviations and was well tolerated without serious adverse events. rhGH treatment was also associated with clinical improvement in social withdrawal, hyperactivity, and sensory symptoms. LIMITATIONS: Results should be interpreted with caution given the small sample size and lack of a placebo control. CONCLUSIONS: Overall, findings are promising and indicate the need for larger studies with rhGH in PMS. Trial registration NCT04003207. Registered July 1, 2019, https://clinicaltrials.gov/ct2/show/NCT04003207 . En ligne : http://dx.doi.org/10.1186/s13229-022-00485-7 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=459 [article] A proof-of-concept study of growth hormone in children with Phelan-McDermid syndrome [texte imprimé] / S. SETHURAM, Auteur ; Tess LEVY, Auteur ; Jennifer H. FOSS-FEIG, Auteur ; Danielle B. HALPERN, Auteur ; Sven SANDIN, Auteur ; Paige M. SIPER, Auteur ; Hugh WALKER, Auteur ; Joseph D. BUXBAUM, Auteur ; Robert RAPAPORT, Auteur ; Alexander KOLEVZON, Auteur . - 6p. Langues : Anglais (eng) in Molecular Autism > 13 (2022) . - 6p. Mots-clés : Asd  Autism spectrum disorder  Growth hormone  Igf-1  Insulin-like growth factor-1  Pms  Phelan–McDermid syndrome  Shank3  Jaguar, Neuren, GW Pharma, and Ovid Therapeutics. JDB has a shared patent with Mount  Sinai for IGF-1 in Phelan–McDermid syndrome. No other authors have competing  interests to disclose. Index. décimale : PER Périodiques Résumé : BACKGROUND: Phelan-McDermid syndrome (PMS) is caused by 22q13 deletions including SHANK3 or pathogenic sequence variants in SHANK3 and is among the more common rare genetic findings in autism spectrum disorder (ASD). SHANK3 is critical for synaptic function, and preclinical and clinical studies suggest that insulin-like growth factor-1 (IGF-1) can reverse a range of deficits in PMS. IGF-1 release is stimulated by growth hormone secretion from the anterior pituitary gland, and this study sought to assess the feasibility of increasing IGF-1 levels through recombinant human growth hormone (rhGH) treatment, in addition to establishing safety and exploring efficacy of rhGH in children with PMS. METHODS: rhGH was administered once daily for 12 weeks to six children with PMS using an open-label design. IGF-1 levels, safety, and efficacy assessments were measured every 4 weeks throughout the study. RESULTS: rhGH administration increased levels of IGF-1 by at least 2 standard deviations and was well tolerated without serious adverse events. rhGH treatment was also associated with clinical improvement in social withdrawal, hyperactivity, and sensory symptoms. LIMITATIONS: Results should be interpreted with caution given the small sample size and lack of a placebo control. CONCLUSIONS: Overall, findings are promising and indicate the need for larger studies with rhGH in PMS. Trial registration NCT04003207. Registered July 1, 2019, https://clinicaltrials.gov/ct2/show/NCT04003207 . En ligne : http://dx.doi.org/10.1186/s13229-022-00485-7 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=459